KY-1

KY-1 is a preclinical small molecule inhibitor of the eukaryotic initiation factor 4A (eIF4A) RNA helicase, developed by Keye Life Sciences (Kaiyue Biotech) for the treatment of solid tumors. As a key component of the eIF4F translation initiation complex, eIF4A is responsible for unwinding complex secondary structures in the 5' untranslated regions (UTRs) of mRNAs, a step necessary for ribosome scanning and protein synthesis. Many oncogenic drivers, including MYC, cyclin D1, and BCL-2, are highly dependent on eIF4A for their translation. By inhibiting eIF4A, KY-1 selectively suppresses the production of these proteins, leading to growth arrest and apoptosis in cancer cells while sparing normal cells that are less dependent on this specific translation mechanism.